Year: 2025

(All dollar amounts are expressed in Canadian dollars, unless stated otherwise) HIGHLIGHTS Q3 2025 (at September 30, 2025)~$401.4 million in cash and cash equivalents Drawn ~$137.2 million (US$100.0 million) under the US$450 million Appian financing facility executed during the quarter Completed private placements for ~$280.4 million (US$203.1 million) in gross proceeds Advanced pre-construction activities and underground mine development activities, and announced results of ore sorting and drilling programs at the permitted Cariboo Gold Project Sold 877 ounces of gold from the Tintic small-scale heap leach projectSubsequent to Q3 2025Completed an additional private placement for ~$82.5 million in gross proceeds Released infill drill results from the ongoing program at Cariboo; appointed Scott Smith as VP, ExplorationMONTREAL,...

Net Contribution grew by 28% year-over-year to $215 millionAssets Under Administration grew by 76% year-over-year to $20.8 billionFunded accounts grew by 16% year-over-year to 3.73 millionAnnounced a $150 million share repurchase program NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — eToro Group Ltd. (“eToro”, or the “Company”) (NASDAQ: ETOR), the trading and investing platform, today announced financial results for the third quarter ended September 30, 2025. “We  remain focused on executing our strategy across our four  key pillars of trading, investing, wealth management, and neo-banking, developing new products and services that deliver value to users across every step of their investing journey. This robust product offering, combined with our unique shared social experience for users worldwide, creates a powerful flywheel that...

Consolidated Net Sales Increased 21% YoY to $66.7 Million; International Export Sales Increased 758% Consolidated Net Income from Continuing Ops of $10.8 Million or $0.09 Per Share, Up YoY and Sequentially  Consolidated Adjusted EBITDA of $20.2 Million or 30.3% of Sales; Both Company Records Operating Cash Flow of $24.4 Million Brings YTD Total to $46.7 Million; Company Ends Quarter with Approximately $88 Million in Cash Canadian Cannabis Delivers Record Net Sales, Record Gross Margin of 56%, Record Adj. EBITDA and Record Cash Flow from Operations; 40 Metric Ton Production Capacity Expansion Underway Continued Momentum in Netherlands Cannabis Sales as Capacity Expansion Progresses on ScheduleVANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ:...

Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter; Access for 275,000 total patients across customer base expected by year-end Vadadustat post-hoc data analysis presented at ASN Kidney Week demonstrates composite of all-cause mortality and hospitalization outcomes statistically more favorable for patients receiving vadadustat compared to ESAs Akebia to host Conference Call at 8:00 a.m. ET on Monday, November 10, 2025 CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) — Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended...

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD in Q2 2026, and APG279 Phase 1b head-to-head readout against DUPIXENT in AD in 2H 2026 Interim Phase 1 results of APG333 in healthy volunteers reported today exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6-month dosing and the development of a quarterly or less frequently dosed co-formulation of APG273 (APG777+APG333) for respiratory indications Completed $345 million public offering; $913 million cash, cash equivalents and marketable securities pro forma as of September...

~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progression at 36 months and supportive trends across key clinical and biomarker endpoints ~ ~ Preliminary feedback from FDA at a recent pre-Biologics License Application (BLA) meeting for AMT-130 indicated a key shift from prior regulatory communications; uniQure plans to urgently interact with the FDA to define next steps ~ ~ Advanced enrollment of Phase I/IIa study of AMT-260 in mesial temporal lobe epilepsy, with additional clinical data expected in the first half of 2026 ~ ~ Presented initial data from Phase I/IIa study of AMT-191 in Fabry disease showing sustained increases in α-gal enzyme activity in patients with Fabry disease; additional...